# US 10,308,710 B2 · Humanized anti-Tau(pS422) antibodies and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,308,710 B2
- Document ID: US10308710B2
- Status: Granted
- Kind: B2
- Application number: 15/389,286
- Filed: 2016-12-22
- Published: 2017-05-11
- Granted: 2019-06-04
- Earliest claimed: 2013-12-20
- Assignees: Hoffmann-La Roche Inc.
- Applicants: Hoffmann-La Roche Inc.
- Inventors: Fiona Grueninger; Guy Georges; Olaf Mundigl; Michael Schraeml; Bernd Bohrmann; Ulrich Goepfert; Joerg Benz; Hubert Kettenberger
- Web page: https://patentgrep.com/patent/US10308710B2

## CPC

- C07K 16/18: against material from animals or humans
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- C07K 14/4711: {Alzheimer's disease; Amyloid plaque core protein}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.

## Claims

### Claim 1

A humanized antibody that specifically binds to human Tau(pS422), wherein the antibody comprises
in the light chain:
a HVR-L1 comprising SEQ ID NO: 12,
a HVR-L2 comprising SEQ ID NO: 5, and
a HVR-L3 comprising SEQ ID NO: 6,
and
in the heavy chain:
a HVR-H1 comprising SEQ ID NO: 8,
a HVR-H2 comprising SEQ ID NO: 9 or 18, and
a HVR-H3 comprising SEQ ID NO: 10.

### Claim 2 (depends on 1)

A pharmaceutical formulation comprising the humanized antibody according to claim 1 and a pharmaceutically acceptable carrier.

### Claim 3 (depends on 2)

The pharmaceutical formulation according to claim 2, further comprising an antihuman alpha-synuclein antibody or an anti-Abeta antibody.

### Claim 4 (depends on 1)

A method for treating Alzheimer's disease, said method comprising administering to a patient in need thereof, a pharmaceutically effective amount of the humanized antibody of claim 1, and wherein the Alzheimer's disease is prodromal Alzheimer's disease, or mild Alzheimer's disease.

### Claim 5 (depends on 1)

A method for reducing Tau(pS422) induced neurodegeneration, said method comprising administering the humanized antibody of claim 1 to a patient in need of thereof.

### Claim 6 (depends on 4)

The method according to claim 4, wherein the humanized antibody is for maintaining cognition and function.